{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2024"],"submitter":["Langslet G"],"pubmed_abstract":["<b>Objective</b>: To evaluate the effectiveness of empagliflozin in reducing all-cause mortality (ACM), hospitalization for heart failure (HHF), myocardial infarction (MI), stroke, cardiovascular mortality (CVM), and end-stage renal disease (ESRD) in routine clinical practice in the Nordic countries of the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) study. <b>Methods</b>: This noninterventional, multicountry cohort study used secondary data from four Nordic countries (Denmark, Sweden, Finland, and Norway). Propensity score (PS) matched (1:1) adults with type 2 diabetes (T2D) initiating empagliflozin (a sodium-glucose cotransporter-2 inhibitor) during 2014-2018 who were compared to those initiating a dipeptidyl peptidase-4 inhibitor (DPP-4i). Cox proportional hazards regres"],"journal":["Journal of diabetes research"],"pagination":["6142211"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11490347"],"repository":["biostudies-literature"],"pubmed_title":["Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study."],"pmcid":["PMC11490347"],"pubmed_authors":["Langslet G","Grip ET","Niskanen L","Vistisen D","Halvorsen S","Farsani SF","Lajer M","Hoti F","Ofstad AP","Carstensen B","Tskhvarashvili G","Tuovinen M","Klement R","Koeneman L","Karlsdotter K","Nystrom T","Shay C","Casajust P"],"additional_accession":[]},"is_claimable":false,"name":"Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.","description":"<b>Objective</b>: To evaluate the effectiveness of empagliflozin in reducing all-cause mortality (ACM), hospitalization for heart failure (HHF), myocardial infarction (MI), stroke, cardiovascular mortality (CVM), and end-stage renal disease (ESRD) in routine clinical practice in the Nordic countries of the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) study. <b>Methods</b>: This noninterventional, multicountry cohort study used secondary data from four Nordic countries (Denmark, Sweden, Finland, and Norway). Propensity score (PS) matched (1:1) adults with type 2 diabetes (T2D) initiating empagliflozin (a sodium-glucose cotransporter-2 inhibitor) during 2014-2018 who were compared to those initiating a dipeptidyl peptidase-4 inhibitor (DPP-4i). Cox proportional hazards regres","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-18T13:09:54.424Z","creation":"2025-04-06T22:42:54.663Z"},"accession":"S-EPMC11490347","cross_references":{"pubmed":["39430801"],"doi":["10.1155/2024/6142211"]}}